CurrentMedical Mutual - OhioPolicy N/A

Litfulo (ritlecitinib) — Coverage Criteria for Alopecia Areata

This policy governs prior authorization and medical necessity criteria for Litfulo (ritlecitinib) for treatment of alopecia areata in patients ≥12 years, including initial and continuation approval requirements, and lists conditions not recommended for approval. It applies to Medical Mutual - Ohio pharmacy benefit coverage decisions.

Policy Summary

PayerMedical Mutual - Ohio

PolicyLitfulo (ritlecitinib) — Coverage Criteria for Alopecia Areata

Policy CodePolicy N/A

Change TypeAnnual review — no material changes

Effective DateN/A

Next Review DateDec 18, 2025

Key ActionObtain prior authorization and ensure prescription is by or in consultation with a dermatologist.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

≥12min patient age

≥6 moepisode duration (initial)

≥50%scalp hair loss threshold

6 moinitial approval

1 yrcontinuation approval

Coverage Criteria for Litfulo (ritlecitinib)

Policy Summary

PayerMedical Mutual - Ohio

PolicyLitfulo (ritlecitinib) — Coverage Criteria for Alopecia Areata

Policy CodePolicy N/A

Change TypeAnnual review — no material changes

Effective DateN/A

Next Review DateDec 18, 2025

Key ActionObtain prior authorization and ensure prescription is by or in consultation with a dermatologist.

SourceLink

On This Page

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Initial Therapy (A)

Approve for 6 months if ALL of the following are met

Initial Therapy criteria: Patient is ≥ 12 years of age.

Initial Therapy criteria: Current episode of alopecia areata lasting ≥ 6 months.

Initial Therapy criteria: Patient has ≥ 50% scalp hair loss.

Initial Therapy criteria

ONE of: Conventional systemic therapy (examples include corticosteroids, methotrexate, cyclosporine).
ONE of: High- or super-high potency topical corticosteroid.
Exception to the conventional systemic therapy trial allowed if patient has already tried Leqselvi (deuruxolitinib) or Olumiant (baricitinib).

Initial Therapy criteria: Hair loss is not due to androgenetic alopecia, chemotherapy-induced hair loss, trichotillomania, telogen effluvium, systemic lupus erythematosus, or other causes other than alopecia areata.

Initial Therapy criteria: Medication is prescribed by or in consultation with a dermatologist.

Authorization duration: If all criteria met, approve for 6 months (180 days).

Continuation / Currently Receiving Litfulo

Approve for 1 year if ALL of the following are met

Continuation criteria: Patient is ≥ 12 years of age.

Continuation criteria: Patient has been established on Litfulo for at least 6 months (patients with <6 months or restarting are reviewed under Initial Therapy).

Continuation criteria: Patient experienced a beneficial clinical response defined as improvement from baseline in extent and density of scalp hair loss.

Continuation criteria: Prescriber states the patient continues to require systemic therapy for treatment of alopecia areata.

Concurrent administration of Litfulo with another biologic or with a targeted synthetic oral small molecule drug used for inflammatory conditions is not recommended. The policy states that Litfulo "should not be administered in combination with another biologic or with a targeted synthetic oral small molecule drug" because combination therapy is associated with a potentially higher rate of adverse events and there are no controlled clinical data supporting additive efficacy (see examples in the Appendix).

Concurrent use of Litfulo with a topical JAK inhibitor (for example, ruxolitinib cream/Opzelura) is also not recommended; the policy specifies that Litfulo "should not be administered in combination with another JAKi" due to potential for increased adverse effects and lack of evidence for added benefit.

Prescribers should therefore avoid co-prescribing Litfulo with other biologics, targeted synthetic oral small molecules for inflammatory indications, or topical JAK inhibitors when seeking coverage under this policy.

The policy identifies that coverage is not recommended for circumstances that are not explicitly listed in the Recommended Authorization Criteria. This list will be revised as new published data become available; until then, requests that fall outside the stated authorization criteria are not supported by this policy.

Combination therapy with other immune-modulating agents is not recommended. Specifically, Litfulo should not be used in combination with other biologics, other JAK inhibitors (including topical JAKi), biologic immunomodulators (examples listed in the policy include tralokinumab, reslizumab, dupilumab, benralizumab, mepolizumab, tezepelumab, omalizumab), or other potent immunosuppressants such as cyclosporine or azathioprine.

The rationale provided is the increased risk of additive immunosuppression and adverse events and the absence of evaluative data demonstrating additive efficacy for these combinations. Requests for combination use will therefore not meet the policy’s Recommended Authorization Criteria.

Provider Requirements, Documentation, and Prior Authorization

Prior Authorization

Specialist Prescriber / Consultation Required

Initial approval requires the medication be prescribed by or in consultation with a physician who specializes in the condition being treated (e.g., dermatologist for alopecia areata). All approvals for initial therapy are for the initial approval duration noted in the Criteria; reauthorization (when allowed) requires documented response to therapy unless otherwise specified.

Initial prescriber or consultation required for initial approvals (specialist).

Step Therapy

Required Prior Trial(s) Before Initial Therapy

Prior authorization is recommended for pharmacy benefit coverage. For some indications, initial approval requires documentation that the patient has tried at least one conventional systemic therapy (examples: corticosteroids, methotrexate, cyclosporine) or appropriate topical therapy prior to starting this medication. Exceptions to the trial requirement may apply if the patient has previously tried specific alternative agents as noted in the Criteria.

Required prior trial of at least one conventional systemic therapy or specified topical agent before initial therapy; documented exceptions noted in Criteria.

Documentation Required

Documentation May Be Requested

The Company reserves the right to request additional documentation to support coverage determinations. Documentation that may be requested includes patient medical records, relevant test results, and credentials of the provider ordering or performing the service. Providers must make additional documentation supporting medical necessity available upon request.

Patient records, diagnostic test results, and/or provider credentials may be requested to substantiate medical necessity.

Denial Risk

Denial Conditions / Reimbursement Risk

The Company may deny reimbursement when the drug or services are determined to be not medically necessary, investigational/experimental, not within the member's benefit scope, or when a pattern of inappropriate or excessive billing or other practice is identified. The Company also reserves the right to modify or interpret this policy at its sole discretion.

Denial possible for not medically necessary, investigational/experimental use, out-of-benefit services, or inappropriate/excessive billing patterns.

OpenPayer

Litfulo (ritlecitinib) — Coverage Criteria for Alopecia Areata

Coverage Criteria for Litfulo (ritlecitinib)

Key Clinical Thresholds and Definitions

Provider Requirements, Documentation, and Prior Authorization

Background on Litfulo (ritlecitinib)

Definitions and Subtypes